P2 Multi-center Study of SB204 Gel in the Treatment of Acne Vulgaris

A Phase 2, Multi-Center, Randomized, Evaluator-Blinded, Vehicle-Controlled Study Comparing the Efficacy, Tolerability, and Safety of SB204 Gel and Vehicle Gel Once or Twice Daily in the Treatment of Acne Vulgaris

This is a randomized, multi-center, double-blinded study in subjects with moderate to severe acne vulgaris. Subjects eligible to enroll will be treated once or twice daily with 2 concentrations of a topical drug in development or a vehicle. Subjects will be treated for up to 12 weeks.

A randomized, multi-center, double-blinded study in subjects with moderate to severe acne vulgaris. Subjects eligible to enroll will be treated once or twice daily with 2 concentrations of a topical drug in development or a vehicle. Subjects will be treated for up to 12 weeks.

Inclusion Criteria:

• Moderate to severe acne
• 25-70 non-inflammatory lesions at Baseline
• 20-40 inflammatory lesions at Baseline

Exclusion Criteria:

• Subjects with known allergy to any component of the test material or vehicle
• Women who are pregnant or nursing